Elizabeth I Pierpont1, Julie B Eisengart1, Ryan Shanley2, David Nascene3, Gerald V Raymond4, Elsa G Shapiro5, Rich S Ziegler1, Paul J Orchard6, Weston P Miller6. 1. Division of Clinical Behavioral Neuroscience, Department of Pediatrics, University of Minnesota, Minneapolis. 2. Biostatistics and Bioinformatics Core, University of Minnesota Masonic Cancer Center, Minneapolis. 3. Department of Radiology, University of Minnesota, Minneapolis. 4. Department of Neurology, University of Minnesota, Minneapolis. 5. Division of Clinical Behavioral Neuroscience, Department of Pediatrics, University of Minnesota, Minneapolis5Shapiro & Delaney LLC, University of Minnesota, Minneapolis. 6. Division of Blood and Marrow Transplantation, Department of Pediatrics, University of Minnesota, Minneapolis.
Abstract
Importance: Untreated childhood cerebral adrenoleukodystrophy (cALD) is a fatal disease associated with progressive cerebral demyelination and rapid, devastating neurologic decline. The standard of care to enhance long-term survival and stabilize cerebral disease is a hematopoietic stem cell transplant (HSCT). Neurologic outcomes are better when HSCT occurs at an earlier stage of cALD, yet there is limited understanding of the neurocognitive trajectory of patients who undergo HSCT. Objectives: To characterize neurocognitive outcomes of boys with cALD and early-stage cerebral disease who were treated with an allogeneic HSCT and to identify disease- and treatment-related factors associated with long-term functioning. Design, Setting, and Participants: Baseline and follow-up neurocognitive test performance was analyzed for all boys with cALD who received an HSCT at the University of Minnesota between January 1, 1991, and October 20, 2014, and who had a pretransplant magnetic resonance imaging (MRI) severity score of less than 10 (scale range, 0-34; higher scores indicate greater severity). Main Outcomes and Measures: Longitudinal neurocognitive test performance in 4 domains (verbal comprehension, perceptual [visual] reasoning, working memory, and processing speed) were the primary outcome measures. Secondary analysis at the most recent evaluation also included measures of sustained attention, verbal memory, visual-motor integration, and fine motor function. Results: Among the 62 boys in this study (mean [SD] age at transplant, 8.37 [2.80] years; range, 4-16 years), there was a significant association of pretransplant MRI severity and baseline verbal comprehension (r = -0.340; P = .008), perceptual reasoning (r = -0.419; P = .001), and processing speed (r = -0.285; P = .03) scores. Higher pretransplant MRI severity scores were also associated with a steeper decline in neurocognitive functioning during the 5-year follow-up period. Twenty-two of 33 patients (67%) with available long-term follow-up neurocognitive testing had severe impairment in at least 1 neurocognitive domain at the most recent evaluation. Conclusions and Relevance: Boys with cALD who have greater than minimal cerebral disease detected on MRI scans at the time of an HSCT are at risk for severe, persistent neurocognitive deficits. These findings motivate further exploration of methods of detecting cerebral disease prior to development of lesions observable on MRI scans, an endeavor that may be facilitated by newborn screening for adrenoleukodystrophy. These findings may serve a benchmark role in evaluating the efficacy of novel interventions for cALD.
Importance: Untreated childhood cerebral adrenoleukodystrophy (cALD) is a fatal disease associated with progressive cerebral demyelination and rapid, devastating neurologic decline. The standard of care to enhance long-term survival and stabilize cerebral disease is a hematopoietic stem cell transplant (HSCT). Neurologic outcomes are better when HSCT occurs at an earlier stage of cALD, yet there is limited understanding of the neurocognitive trajectory of patients who undergo HSCT. Objectives: To characterize neurocognitive outcomes of boys with cALD and early-stage cerebral disease who were treated with an allogeneic HSCT and to identify disease- and treatment-related factors associated with long-term functioning. Design, Setting, and Participants: Baseline and follow-up neurocognitive test performance was analyzed for all boys with cALD who received an HSCT at the University of Minnesota between January 1, 1991, and October 20, 2014, and who had a pretransplant magnetic resonance imaging (MRI) severity score of less than 10 (scale range, 0-34; higher scores indicate greater severity). Main Outcomes and Measures: Longitudinal neurocognitive test performance in 4 domains (verbal comprehension, perceptual [visual] reasoning, working memory, and processing speed) were the primary outcome measures. Secondary analysis at the most recent evaluation also included measures of sustained attention, verbal memory, visual-motor integration, and fine motor function. Results: Among the 62 boys in this study (mean [SD] age at transplant, 8.37 [2.80] years; range, 4-16 years), there was a significant association of pretransplant MRI severity and baseline verbal comprehension (r = -0.340; P = .008), perceptual reasoning (r = -0.419; P = .001), and processing speed (r = -0.285; P = .03) scores. Higher pretransplant MRI severity scores were also associated with a steeper decline in neurocognitive functioning during the 5-year follow-up period. Twenty-two of 33 patients (67%) with available long-term follow-up neurocognitive testing had severe impairment in at least 1 neurocognitive domain at the most recent evaluation. Conclusions and Relevance: Boys with cALD who have greater than minimal cerebral disease detected on MRI scans at the time of an HSCT are at risk for severe, persistent neurocognitive deficits. These findings motivate further exploration of methods of detecting cerebral disease prior to development of lesions observable on MRI scans, an endeavor that may be facilitated by newborn screening for adrenoleukodystrophy. These findings may serve a benchmark role in evaluating the efficacy of novel interventions for cALD.
Authors: R Lajiness-O'Neill; F Hoodin; R Kentor; K Heinrich; A Colbert; J A Connelly Journal: Arch Clin Neuropsychol Date: 2015-08-27 Impact factor: 2.813
Authors: A M McKinney; D Nascene; W P Miller; J Eisengart; D Loes; M Benson; J Tolar; P J Orchard; R S Ziegler; L Zhang; J Provenzale Journal: AJNR Am J Neuroradiol Date: 2012-08-16 Impact factor: 3.825
Authors: Francieli J Rockenbach; Marion Deon; Daiane P Marchese; Vanusa Manfredini; Caroline Mescka; Graziela S Ribas; Clarissa T Habekost; Claudio G Castro; Laura B Jardim; Carmen R Vargas Journal: Mol Genet Metab Date: 2012-04-03 Impact factor: 4.797
Authors: Jean M Mulcahy Levy; Tiffany Tello; Roger Giller; Greta Wilkening; Ralph Quinones; Amy K Keating; Arthur K Liu Journal: Pediatr Blood Cancer Date: 2012-07-27 Impact factor: 3.167
Authors: D J Loes; S Hite; H Moser; A E Stillman; E Shapiro; L Lockman; R E Latchaw; W Krivit Journal: AJNR Am J Neuroradiol Date: 1994-10 Impact factor: 3.825
Authors: Donald Beam; Michele D Poe; James M Provenzale; Paul Szabolcs; Paul L Martin; Vinod Prasad; Suhag Parikh; Tim Driscoll; Srini Mukundan; Joanne Kurtzberg; Maria L Escolar Journal: Biol Blood Marrow Transplant Date: 2007-04-06 Impact factor: 5.742
Authors: E J Mallack; G Askin; S van de Stadt; P A Caruso; P L Musolino; M Engelen; S N Niogi; F S Eichler Journal: AJNR Am J Neuroradiol Date: 2021-09-09 Impact factor: 4.966
Authors: Eric James Mallack; Keith P Van Haren; Anna Torrey; Stephanie van de Stadt; Marc Engelen; Gerald V Raymond; Ali Fatemi; Florian S Eichler Journal: Neurology Date: 2022-05-24 Impact factor: 11.800
Authors: Eric J Mallack; Bela R Turk; Helena Yan; Carrie Price; Michelle Demetres; Ann B Moser; Catherine Becker; Kim Hollandsworth; Laura Adang; Adeline Vanderver; Keith Van Haren; Maura Ruzhnikov; Joanne Kurtzberg; Gustavo Maegawa; Paul J Orchard; Troy C Lund; Gerald V Raymond; Molly Regelmann; Joseph J Orsini; Elisa Seeger; Stephan Kemp; Florian Eichler; Ali Fatemi Journal: J Inherit Metab Dis Date: 2021-01-09 Impact factor: 4.982
Authors: Afonso P Liberato; Eric J Mallack; Razina Aziz-Bose; Doug Hayden; Arne Lauer; Paul A Caruso; Patricia L Musolino; Florian S Eichler Journal: Neurology Date: 2019-03-22 Impact factor: 11.800
Authors: Elizabeth I Pierpont; Erin McCoy; Kelly E King; Rich S Ziegler; Ryan Shanley; David Nascene; Gerald V Raymond; Rachel Phelan; Troy C Lund; Paul J Orchard; Weston P Miller Journal: Ann Clin Transl Neurol Date: 2018-01-22 Impact factor: 4.511
Authors: Elizabeth I Pierpont; David R Nascene; Ryan Shanley; Daniel L Kenney-Jung; Richard S Ziegler; Weston P Miller; Ashish O Gupta; Troy C Lund; Paul J Orchard; Julie B Eisengart Journal: Neurology Date: 2020-07-02 Impact factor: 9.910